Perrigo's (PRGO) Generic Epiduo Gel Garners Tentative FDA Approval

September 1, 2016 9:04 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Perrigo Company plc (NYSE: PRGO) announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Epiduo Gel (adapalene and benzoyl peroxide 0.1%/2.5%).

Epiduo® Gel (adapalene and benzoyl peroxide 0.1%/2.5%) is indicated for the treatment of acne vulgaris in patients 12 years of age and older. Annual sales for the 12 months ending July 2016 were $379 million.

Perrigo's CEO John T. Hendrickson stated, "This tentative approval is another example of Perrigo's ongoing commitment to developing high quality value alternatives in important treatment categories. The Rx team continues to leverage Perrigo's development capabilities in order to deliver Quality Affordable Healthcare Products® to our customers and consumers around the world."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments

Add Your Comment